BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

120 related articles for article (PubMed ID: 16571650)

  • 1. Osteopontin is a downstream effector of the PI3-kinase pathway in melanomas that is inversely correlated with functional PTEN.
    Packer L; Pavey S; Parker A; Stark M; Johansson P; Clarke B; Pollock P; Ringner M; Hayward N
    Carcinogenesis; 2006 Sep; 27(9):1778-86. PubMed ID: 16571650
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Heterozygous disruption of the PTEN promotes intestinal neoplasia in APCmin/+ mouse: roles of osteopontin.
    Shao J; Washington MK; Saxena R; Sheng H
    Carcinogenesis; 2007 Dec; 28(12):2476-83. PubMed ID: 17693663
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cadherin switch from E- to N-cadherin in melanoma progression is regulated by the PI3K/PTEN pathway through Twist and Snail.
    Hao L; Ha JR; Kuzel P; Garcia E; Persad S
    Br J Dermatol; 2012 Jun; 166(6):1184-97. PubMed ID: 22332917
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Hyaluronic acid induces osteopontin via the phosphatidylinositol 3-kinase/Akt pathway to enhance the motility of human glioma cells.
    Kim MS; Park MJ; Moon EJ; Kim SJ; Lee CH; Yoo H; Shin SH; Song ES; Lee SH
    Cancer Res; 2005 Feb; 65(3):686-91. PubMed ID: 15705860
    [TBL] [Abstract][Full Text] [Related]  

  • 5. C-Jun drives melanoma progression in PTEN wild type melanoma cells.
    Kappelmann-Fenzl M; Gebhard C; Matthies AO; Kuphal S; Rehli M; Bosserhoff AK
    Cell Death Dis; 2019 Aug; 10(8):584. PubMed ID: 31378787
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Phosphoinositide 3-kinase is not overexpressed in melanocytic lesions.
    Singh RS; Diwan AH; Zhang PS; Prieto VG
    J Cutan Pathol; 2007 Mar; 34(3):220-5. PubMed ID: 17302605
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Phosphatidylinositol 3-kinase signaling controls levels of hypoxia-inducible factor 1.
    Jiang BH; Jiang G; Zheng JZ; Lu Z; Hunter T; Vogt PK
    Cell Growth Differ; 2001 Jul; 12(7):363-9. PubMed ID: 11457733
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Roles of the RAF/MEK/ERK and PI3K/PTEN/AKT pathways in malignant transformation and drug resistance.
    McCubrey JA; Steelman LS; Abrams SL; Lee JT; Chang F; Bertrand FE; Navolanic PM; Terrian DM; Franklin RA; D'Assoro AB; Salisbury JL; Mazzarino MC; Stivala F; Libra M
    Adv Enzyme Regul; 2006; 46():249-79. PubMed ID: 16854453
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Could changes in the regulation of the PI3K/PKB/Akt signaling pathway and cell cycle be involved in astrocytic tumor pathogenesis and progression?
    Hlobilkova A; Ehrmann J; Sedlakova E; Krejci V; Knizetova P; Fiuraskova M; Kala M; Kalita O; Kolar Z
    Neoplasma; 2007; 54(4):334-41. PubMed ID: 17822324
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Exploration of genetic alterations in human endometrial cancer and melanoma: distinct tumorigenic pathways that share a frequent abnormal PI3K/AKT cascade.
    Ogawa K; Sun C; Horii A
    Oncol Rep; 2005 Dec; 14(6):1481-5. PubMed ID: 16273242
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Osteopontin-induced migration of human mammary epithelial cells involves activation of EGF receptor and multiple signal transduction pathways.
    Tuck AB; Hota C; Wilson SM; Chambers AF
    Oncogene; 2003 Feb; 22(8):1198-205. PubMed ID: 12606946
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Osteopontin: it's role in regulation of cell motility and nuclear factor kappa B-mediated urokinase type plasminogen activator expression.
    Das R; Philip S; Mahabeleshwar GH; Bulbule A; Kundu GC
    IUBMB Life; 2005 Jun; 57(6):441-7. PubMed ID: 16012053
    [TBL] [Abstract][Full Text] [Related]  

  • 13. PI3K/PTEN/AKT signaling regulates prostate tumor angiogenesis.
    Fang J; Ding M; Yang L; Liu LZ; Jiang BH
    Cell Signal; 2007 Dec; 19(12):2487-97. PubMed ID: 17826033
    [TBL] [Abstract][Full Text] [Related]  

  • 14. PTEN expression causes feedback upregulation of insulin receptor substrate 2.
    Simpson L; Li J; Liaw D; Hennessy I; Oliner J; Christians F; Parsons R
    Mol Cell Biol; 2001 Jun; 21(12):3947-58. PubMed ID: 11359902
    [TBL] [Abstract][Full Text] [Related]  

  • 15. PTEN and melanomagenesis.
    Conde-Perez A; Larue L
    Future Oncol; 2012 Sep; 8(9):1109-20. PubMed ID: 23030486
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Decatenation checkpoint-defective melanomas are dependent on PI3K for survival.
    Brooks K; Ranall M; Spoerri L; Stevenson A; Gunasingh G; Pavey S; Meunier F; Gonda TJ; Gabrielli B
    Pigment Cell Melanoma Res; 2014 Sep; 27(5):813-21. PubMed ID: 24890688
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Distinct sets of genetic alterations in melanoma.
    Curtin JA; Fridlyand J; Kageshita T; Patel HN; Busam KJ; Kutzner H; Cho KH; Aiba S; Bröcker EB; LeBoit PE; Pinkel D; Bastian BC
    N Engl J Med; 2005 Nov; 353(20):2135-47. PubMed ID: 16291983
    [TBL] [Abstract][Full Text] [Related]  

  • 18. PTEN and phosphatidylinositol 3'-kinase inhibitors up-regulate p53 and block tumor-induced angiogenesis: evidence for an effect on the tumor and endothelial compartment.
    Su JD; Mayo LD; Donner DB; Durden DL
    Cancer Res; 2003 Jul; 63(13):3585-92. PubMed ID: 12839945
    [TBL] [Abstract][Full Text] [Related]  

  • 19. E- to N-cadherin switch in melanoma is associated with decreased expression of phosphatase and tensin homolog and cancer progression.
    Lade-Keller J; Riber-Hansen R; Guldberg P; Schmidt H; Hamilton-Dutoit SJ; Steiniche T
    Br J Dermatol; 2013 Sep; 169(3):618-28. PubMed ID: 23662813
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Relative reciprocity of NRAS and PTEN/MMAC1 alterations in cutaneous melanoma cell lines.
    Tsao H; Zhang X; Fowlkes K; Haluska FG
    Cancer Res; 2000 Apr; 60(7):1800-4. PubMed ID: 10766161
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.